Table 5 Association of regulatory polymorphisms and overall survival according to the chemotherapy regimen.

From: Identifying polymorphic cis-regulatory variants as risk markers for lung carcinogenesis and chemotherapy responses in tobacco smokers from eastern India

Regulatory polymorphisms

Genotypes

Crude HR (95% CI)

Log-rank p

Adjusted HR† (95% CI)

p-value†

Regimen 1—Docetaxel cis/carboplatin

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

2.51 (0.35–18.17)

0.3

26.29 (0.18–3762.41)

0.19

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

0.47 (0.04–5.16)

0.5

1.55 (0.03–90.37)

0.83

Regimen 1—Pemetrexed cis/carboplatin

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.28 (0.39–4.15)

0.7

1.8 (0.39–8.19)

0.49

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.42 (0.78–7.47)

0.1

1.33 (0.29–5.89)

0.71

Regimen 1– Paclitaxel cis/carboplatin

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

2.67 (0.93–8.39)

0.06

3.62 (1.03–12.71)

0.044*

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

3.19 (1.10–9.27)

0.02*

1.95 (0.58–6.58)

0.28

Regimen 1– Nanopaclitaxel cis/carboplatin

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.15 (0.19–6.98)

0.9

3.37 (0.24–47.98)

0.37

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

7.95 (0.89–71.16)

0.03*

11.32 (0.18–698.64)

0.25

Regimen 1—Etoposide cis/carboplatin

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

The sample size is insufficient

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

1.01 (0.20–5.08)

0.99

0.78 (0.10–5.97)

0.82

Combination Drug Regimen: Docetaxel cis/carboplatin (2nd) * Nanopaclitaxel cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.15 (0.19–6.98)

0.9

2.05 (0.25–16.55)

0.5

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

7.15 (0.74–69.03)

0.05

16.75 (0.38–734.18)

0.14

Combination Drug Regimen: Nanopaclitaxel cis/carboplatin (2nd) * Pemetrexed cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.40 (0.38–5.10)

0.6

1.39 (0.39–5.31)

0.62

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.27 (0.75–6.84)

0.1

2.35 (0.75–7.37)

0.14

Combination Drug Regimen: Pemetrexed cis/carboplatin (2nd) * Paclitaxel cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

2.47 (0.78–7.84)

0.1

3.25 (0.88–12.06)

0.08

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.97 (1.01–8.76)

0.05

1.75 (0.51–6.07)

0.38

Combination Drug Regimen: Paclitaxel cis/carboplatin (2nd) * Pemetrexed cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.18 (0.32–4.28)

0.8

1.21 (0.33–4.48)

0.78

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

3.10 (0.95–10.16)

0.05

3.41 (0.99–11.81)

0.05

Combination Drug Regimen: Gemcitabine cis/carboplatin (2nd) * Paclitaxel cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

3.02 (1.09–8.39)

0.03*

4.16 (1.34–12.89)

0.014*

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.79 (1.09–7.15)

0.03*

2.12 (0.74–6.11)

0.16

Combination Drug Regimen: Gemcitabine cis/carboplatin (2nd) * Pemetrexed cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.89 (0.74–4.85)

0.2

1.86 (0.70–4.91)

0.21

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.21 (0.88–5.51)

0.08

2.50 (0.94–6.68)

0.07

Combination Drug Regimen: Gemcitabine cis/carboplatin (2nd) * Nanopaclitaxel cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

3.03 (0.78–11.8)

0.09

3.63 (0.93–14.08)

0.06

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

3.28 (0.92–11.67)

0.05

3.38 (0.51–22.24)

0.21

Combination Drug Regimen: Eribulin cis/carboplatin (3rd) * Nanopaclitaxel cis/carboplatin (2nd) * Pemetrexed cis/carboplatin (1st)

 ALDH3B1-rs3764821A > G

AA

1 (Reference)

AG + GG

1.40 (0.38–5.10)

0.6

1.39 (0.37–5.31)

0.62

 RAD52-rs3748523C > G

CC

1 (Reference)

CG + GG

2.26 (0.75–6.84)

0.1

2.35 (0.75–7.37)

0.14

  1. p-value < 0.05*, 0.01**, 0.001***. Hazard ratios, 95% CI, and their corresponding p-values were calculated by Kaplan–Meier survival analysis after adjusting for remission and survival in months, and #adjusted hazard ratios, 95% CIs and their corresponding p-values were calculated by Cox regression models adjusted for age, sex, and pack-years of smoking.
  2. Significant values are in bold and italics.
Back to article page